Mechanism of action
Retatrutide is a novel triple receptor agonist that targets the glucagon-like peptide-1 (GLP-1) receptor, glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. The GLP-1, GIP, and glucagon receptors are all part of the incretin hormone system.
Activation of the GLP-1 receptor promotes insulin secretion, suppresses appetite, and delays gastric emptying. Activation of the GIP receptor enhances insulin sensitivity, accelerates lipolysis, and improves the efficiency of lipid metabolism. Activation of the glucagon receptor increases energy expenditure and promotes fat breakdown.
Research Applications:
– Triple agonist mechanism
– Obesity pharmacotherapy research
– Type 2 diabetes treatment
